biomolecules Article Deamidated Human Triosephosphate Isomerase Is a Promising Druggable Target Sergio Enríquez-Flores 1,*, Luis Antonio Flores-López 1,2, Itzhel García-Torres 1, Ignacio de la Mora-de la Mora 1 , Nallely Cabrera 3, Pedro Gutiérrez-Castrellón 4 , Yoalli Martínez-Pérez 5 and Gabriel López-Velázquez 1,* 1 Grupo de Investigación en Biomoléculas y Salud Infantil, Laboratorio de EIMyT, Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City 04530, Mexico;
[email protected] (L.A.F.-L.);
[email protected] (I.G.-T.);
[email protected] (I.d.l.M.-d.l.M.) 2 CONACYT-Instituto Nacional de Pediatría, Secretaría de Salud, Mexico City 04530, Mexico 3 Departamento de Bioquímica y Biología Estructural, Instituto de Fisiología Celular, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico;
[email protected] 4 Hospital General Dr. Manuel Gea González, Mexico City 14080, Mexico;
[email protected] 5 Unidad de Investigación en Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico;
[email protected] * Correspondence:
[email protected] (S.E.-F.);
[email protected] (G.L.-V.); Tel.: +52-55-10840900 (G.L.-V.) Received: 9 June 2020; Accepted: 10 July 2020; Published: 15 July 2020 Abstract: Therapeutic strategies for the treatment of any severe disease are based on the discovery and validation of druggable targets. The human genome encodes only 600–1500 targets for small-molecule drugs, but posttranslational modifications lead to a considerably larger druggable proteome. The spontaneous conversion of asparagine (Asn) residues to aspartic acid or isoaspartic acid is a frequent modification in proteins as part of the process called deamidation.